Abstract

My aims and objectives for this Outstanding Investigator Award are to continue studies of the biology and treatment of cancer using antibodies and immunotoxins. Research will be directed towards improving the therapy of leukemia and lymphoma, particularly ALL.
The specific aims are to continue laboratory studies of the ontogeny of rearrangement and expression of genes of the immunoglobulin family, particularly the T-cell receptor genes in leukemic cells. My laboratory will characterize, clone and express genes from antibodies with reactivity against leukemic cells with the long term goal of producing antibody-toxin fusion proteins for therapeutic use. In our therapeutic studies my colleagues and I will continue the evaluation of monoclonal antibodies and early generation immunotoxins in ALL and lymphoma.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Unknown (R35)
Project #
5R35CA049721-10
Application #
2700422
Study Section
Special Emphasis Panel (SRC (90))
Program Officer
Wu, Roy S
Project Start
1989-05-01
Project End
2001-04-30
Budget Start
1998-05-01
Budget End
1999-04-30
Support Year
10
Fiscal Year
1998
Total Cost
Indirect Cost

  Institution

Name
University of Minnesota Twin Cities
Department
Pathology
Type
Schools of Medicine
DUNS #
168559177
City
Minneapolis
State
MN
Country
United States
Zip Code
55455

  Publications

Johnson, Jennifer J; Chen, Weili; Hudson, Wendy et al. (2003) Prenatal and postnatal myeloid cells demonstrate stepwise progression in the pathogenesis of MLL fusion gene leukemia. Blood 101:3229-35
Li, Q; Hudson, W; Wang, D et al. (1998) Pharmacokinetics and biodistribution of radioimmunoconjugates of anti-CD19 antibody and single-chain Fv for treatment of human B-cell malignancy. Cancer Immunol Immunother 47:121-30
Hudson, W A; Li, Q; Le, C et al. (1998) Xenotransplantation of human lymphoid malignancies is optimized in mice with multiple immunologic defects. Leukemia 12:2029-33
Li, Q; Frestedt, J L; Kersey, J H (1998) AF4 encodes a ubiquitous protein that in both native and MLL-AF4 fusion types localizes to subnuclear compartments. Blood 92:3841-7
Kersey, J H; Wang, D; Oberto, M (1998) Resistance of t(4;11) (MLL-AF4 fusion gene) leukemias to stress-induced cell death: possible mechanism for extensive extramedullary accumulation of cells and poor prognosis. Leukemia 12:1561-4
Weisdorf, D J; Verfaille, C M; Miller, W J et al. (1997) Autologous bone marrow versus non-mobilized peripheral blood stem cell transplantation for lymphoid malignancies: a prospective, comparative trial. Am J Hematol 54:202-8
Wang, D; Berven, E; Li, Q et al. (1997) Optimization of conditions for formation and analysis of anti-CD19 FVS191 single-chain Fv homodimer (scFv')2. Bioconjug Chem 8:64-70
Lindstrom, A L; Erlandsen, S L; Kersey, J H et al. (1997) An in vitro model for toxin-mediated vascular leak syndrome: ricin toxin A chain increases the permeability of human endothelial cell monolayers. Blood 90:2323-34
Wang, D; Li, Q; Hudson, W et al. (1997) Generation and characterization of an anti-CD19 single-chain Fv immunotoxin composed of C-terminal disulfide-linked dgRTA. Bioconjug Chem 8:878-84
Hilden, J M; Frestedt, J L; Kersey, J H (1997) Molecular analysis of infant acute leukemia. Leuk Lymphoma 25:191-9

Showing the most recent 10 out of 57 publications